[1] [1] PRABHU S D, FRANGOGIANNIS N G. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis[J]. Circ Res, 2016, 119(1): 91-112.

[2] [2] HILGENDORF I, FRANTZ S, FRANGOGIANNIS N G. Repair of the infarcted heart: cellular effectors, molecular mechanisms and therapeutic opportunities[J]. Circ Res, 2024, 134(12): 1718-1751.

[3] [3] BONAVENTURA A, MORONI F, GOLINO M, et al. IL-1 blockade in cardiovascular disease: an appraisal of the evidence across different inflammatory paradigms[J]. Minerva Cardiol Angiol, 2024, 72(5): 477-488.

[4] [4] BUCKLEY L F, ABBATE A. Interleukin-1 blockade in cardiovascular diseases: a clinical update[J]. Eur Heart J, 2018, 39(22): 2063-2069.

[5] [5] RIDKER P M, EVERETT B M, THUREN T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131.

[6] [6] FUNDERBURG N T, SHIVE C L, CHEN Z Y, et al. Interleukin 6 blockade with tocilizumab diminishes indices of inflammation that are linked to mortality in treated human immunodeficiency virus infection[J]. Clin Infect Dis, 2023, 77(2): 272-279.

[7] [7] ZHANG Q Z, DEHAINI D, ZHANG Y, et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis[J]. Nat Nanotechnol, 2018, 13(12): 1182-1190.

[8] [8] VOISIN M B, LEONI G, WOODFIN A, et al. Neutrophil elastase plays a non-redundant role in remodeling the venular basement membrane and neutrophil diapedesis post-ischemia/reperfusion injury[J]. J Pathol, 2019, 248(1): 88-102.

[9] [9] HORCKMANS M, RING L, DUCHENE J, et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype[J]. Eur Heart J, 2017, 38(3): 187-197.

[10] [10] PUHL S L, STEFFENS S. Neutrophils in post-myocardial infarction inflammation: damage vs. resolution?[J]. Front Cardiovasc Med, 2019, 6: 25.

[11] [11] FRANGOGIANNIS N G. Regulation of the inflammatory response in cardiac repair[J]. Circ Res, 2012, 110(1): 159-173.

[12] [12] SUN K, LI Y Y, JIN J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair[J]. Signal Transduct Target Ther, 2021, 6(1): 79.

[13] [13] SILVIS M J M, KAFFKA GENAAMD DENGLER S E, ODILLE C A, et al. Damage-associated molecular patterns in myocardial infarction and heart transplantation: the road to translational success[J]. Front Immunol, 2020, 11: 599511.

[14] [14] FRANGOGIANNIS N G. Transforming growth factor- in myocardial disease[J]. Nat Rev Cardiol, 2022, 19(7): 435-455.

[15] [15] SHINDE A V, DOBACZEWSKI M, DE HAAN J J, et al. Tissue transglutaminase induction in the pressure-overloaded myocardium regulates matrix remodelling[J]. Cardiovasc Res, 2017, 113(8): 892-905.

[16] [16] LEY K, LAUDANNA C, CYBULSKY M I, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated[J]. Nat Rev Immunol, 2007, 7(9): 678-689.

[17] [17] KANG T, ZHU Q Q, WEI D, et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis[J]. ACS Nano, 2017, 11(2): 1397-1411.

[18] [18] SADIK C D, KIM N D, LUSTER A D. Neutrophils cascading their way to inflammation[J]. Trends Immunol, 2011, 32(10): 452-460.

[19] [19] GABRIEL A S, MARTINSSON A, WRETLIND B, et al. IL-6 levels in acute and post myocardial infarction: their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure[J]. Eur J Intern Med, 2004, 15(8): 523-528.

[20] [20] KEHMEIER E S, LEPPER W, KROPP M, et al. TNF-, myocardial perfusion and function in patients with ST-segment elevation myocardial infarction and primary percutaneous coronary intervention[J]. Clin Res Cardiol, 2012, 101(10): 815-827.

[21] [21] HAYDEN M S, GHOSH S. Regulation of NF-B by TNF family cytokines[J]. Semin Immunol, 2014, 26(3): 253-266.

[22] [22] FAN D P, WANG S Q, HUANG R, et al. Light-assisted “nano-neutrophils” with high drug loading for targeted cancer therapy[J]. Int J Nanomed, 2023, 18: 6487-6502.

[23] [23] SIMPKINS C, MONCURE M, KLEPACZ H, et al. Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial[J]. EClinicalMedicine, 2024, 68: 102430.

[24] [24] CHEN Q Y, CHEN Y T, SUN Y L, et al. Leukocyte–mimicking pluronic–lipid nanovesicle hybrids inhibit the growth and metastasis of breast cancer[J]. Nanoscale, 2019, 11(12): 5377-5394.